-logo.jpg){kind=logo}
Hangzhou Just Biotherapeutics (Just China)
Empowering biomedicine with innovative design and cost-effective manufacturing.
Empowering biomedicine with innovative design and cost-effective manufacturing.
Hangzhou Just Biotherapeutics (Just China) is a tech company that was founded in 2015 with a focus on empowering biomedicine through innovative design and cost-effective manufacturing. The company specializes in biopharma, biotechnology, health care, and pharmaceutical industries. Their commitment to accelerating bio-medicine development and reducing manufacturing expenses is evident in their expertise in molecular design, process design, drug product design, and manufacturing plant design.
The company recently secured a substantial $35.00M Series B investment on 06 June 2018. The investment was backed by notable venture capital firms including Arch Venture Partners, Lilly Asia Ventures, Taikang Asset, Temasek Holdings, Hillhouse Investment, and BOCGI Zheshang Capital.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $35.00M | 6 |
|
06 Jun 2018 |
| Series B | CNY400.00M | 4 |
|
08 Aug 2017 |
| Series A | $14.00M | - | 25 Jul 2016 | |
| Series A | $15.00M | - | 21 Sep 2015 | |
| Grant | $24.00M | - | 01 Jan 2015 |
No recent news or press coverage available for Hangzhou Just Biotherapeutics (Just China).
We care about your data, and we'd love to use cookies make your experience better.
